STUDY OF THE APPEARANCE OF LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pulmonary Fibrosis
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Pulmonary fibrotic changes, short and medium term
- Last Updated
- 5 years ago
Overview
Brief Summary
Prospective, observational, multicenter study that will evaluate the changes in lung function that patients admitted with SARS-CoV-2 pneumonia will present according to the level of severity at 4, 12, 26 and 52 weeks after hospital discharge.
Detailed Description
The project consists of a prospective, observational, multicenter study that will evaluate changes in lung function (forced spirometry, measurement of static lung volumes using plethysmography and pulmonary carbon monoxide diffusion test) that patients admitted with pneumonia will present. caused by SARS-CoV-2 according to the level of severity at 4, 12, 26 and 52 weeks after discharge from hospital. Restrictive pulmonary abnormalities will be confirmed by imaging tests (high resolution chest CT).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients admitted for bilateral pneumonia caused by SARS-CoV-2 (confirmed by PCR).
- •Age over 18 years.
- •Acceptance of informed consent.
- •Life expectancy over 1 year.
Exclusion Criteria
- •Patients with a previous diagnosis of interstitial lung disease.
- •Inability to attend review visits.
Outcomes
Primary Outcomes
Pulmonary fibrotic changes, short and medium term
Time Frame: 12 months
To analyze the number of patients who will develop pulmonary fibrotic changes, in the short and medium term, after surviving a bilateral pulmonary infection by SARS-CoV-2
Degree of lung function impairment
Time Frame: 6 and 12 months
To study the degree of lung function impairment, specifically the restrictive changes in functional capacity and diffusion alterations and its relationship with clinical variables.
Biological markers
Time Frame: 1 month
Examine the biological markers in the patients who will present this dysregulation of the curative response that will give rise to pulmonary fibrosing phenomena.